← All trials
NCT04525729
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2020
- Primary completion
- Jul 1, 2023
- Completion date
- Dec 31, 2023
- First posted
- Aug 25, 2020
- Last posted
- Aug 25, 2020
- Enrollment
- 116
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Ruijin Hospital NorthLead sponsor
- Ningxia Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Jiao Tong UniversitySponsor investigator
- Jiao Tong UniversityOverall official - principal investigator
- Zhejiang UniversityCollaborator
- Xiamen Hongai HospitalCollaborator
- Tongji UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Ningbo Yinzhou People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.